{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:03:06Z","timestamp":1792098186668,"version":"4.4.0"},"reference-count":116,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite recent advances with targeted kinase inhibitors and better-tolerated chemotherapy, the treatment of metastatic non\u2013small-cell lung cancer remains suboptimal. One recent advance that holds great promise is immunotherapy\u2014an approach that enhances a patient\u2019s immune system to better recognize and react to abnormal cells. The most successful immunotherapeutic strategy to date uses antibodies to block inhibitory receptors (also called \u201ccheckpoints\u201d) that are up-regulated on the T cells that infiltrate the tumor. Two examples of such molecules are programmed cell death-1 (PD1) and cytotoxic T lymphocyte\u2013associated protein-4. With more than a dozen clinical trials in non\u2013small-cell lung cancer completed, checkpoint blockade targeting PD1 has demonstrated durable responses and superior survival compared with traditional chemotherapy agents when used as first-line therapy in individuals with more than 50% PD1 ligand (PDL1) expression by immunohistochemical staining and as second-line therapy independent of PDL1 status. Antibodies to PDL1 have shown similar activity. Combinations of anti-PD1 and anti-PDL1 with anti\u2013cytotoxic T lymphocyte\u2013associated protein-4 and chemotherapy are being actively tested. These agents have generally tolerable safety profiles; pneumonitis, although rare, remains the most feared adverse effect. PDL1 expression on tumors has been identified as a biomarker predictive of response. Although PDL1 expression has traditionally been measured on resected tumor specimens, the pulmonologist has a growing role in obtaining samples for testing via minimally invasive means.<\/jats:p>","DOI":"10.1513\/annalsats.201702-152fr","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T16:41:51Z","timestamp":1497458511000},"page":"1248-1260","source":"Crossref","is-referenced-by-count":17,"title":["The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System"],"prefix":"10.1093","volume":"14","author":[{"given":"Edmund K.","family":"Moon","sequence":"first","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey J.","family":"Langer","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Albelda","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"key":"2026020403000818700_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"2026020403000818700_bib2","volume-title":"Cancer facts & figures 2017.","author":"American Cancer Society","year":"2017"},{"key":"2026020403000818700_bib3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.athoracsur.2006.08.046","article-title":"Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection","volume":"83","author":"Sugimura","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"2026020403000818700_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000386035","article-title":"The concept of immunological surveillance","volume":"13","author":"Burnet","year":"1970","journal-title":"Prog Exp Tumor Res"},{"key":"2026020403000818700_bib5","first-page":"49","article-title":"Malignant lymphomas in transplantation patients: a review of the world experience","volume":"3","author":"Penn","year":"1970","journal-title":"Int Z Klin Pharmakol Ther Toxikol"},{"key":"2026020403000818700_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/1097-0142(197107)28:1<89::AID-CNCR2820280117>3.0.CO;2-Q","article-title":"Occurrence of malignancy in immunodeficiency diseases: a literature review","volume":"28","author":"Gatti","year":"1971","journal-title":"Cancer"},{"key":"2026020403000818700_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/1097-0142(19890115)63:2<309::AID-CNCR2820630218>3.0.CO;2-N","article-title":"Morphometric and morphologic evaluations in stage III non-small cell lung cancers: prognostic significance of quantitative assessment of infiltrating lymphoid cells","volume":"63","author":"Lee","year":"1989","journal-title":"Cancer"},{"key":"2026020403000818700_bib8","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.2015.63.0970","article-title":"Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer","volume":"34","author":"Brambilla","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026020403000818700_bib9","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1158\/1078-0432.CCR-08-0133","article-title":"Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer","volume":"14","author":"Al-Shibli","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2026020403000818700_bib10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"2026020403000818700_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"2026020403000818700_bib12","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"2026020403000818700_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"2026020403000818700_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/icb.1975.3","article-title":"A new analysis of allogeneic interactions","volume":"53","author":"Lafferty","year":"1975","journal-title":"Aust J Exp Biol Med Sci"},{"key":"2026020403000818700_bib15","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1073\/pnas.87.13.5031","article-title":"T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7\/BB-1","volume":"87","author":"Linsley","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026020403000818700_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol Rev"},{"key":"2026020403000818700_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"2026020403000818700_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2026020403000818700_bib19","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1073\/pnas.94.15.8099","article-title":"Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer","volume":"94","author":"Kwon","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026020403000818700_bib20","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"2026020403000818700_bib21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1074-7613(00)80123-5","article-title":"CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism","volume":"11","author":"Shrikant","year":"1999","journal-title":"Immunity"},{"key":"2026020403000818700_bib22","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1073\/pnas.96.20.11476","article-title":"In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance","volume":"96","author":"Sotomayor","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026020403000818700_bib23","first-page":"4036","article-title":"Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages","volume":"57","author":"Yang","year":"1997","journal-title":"Cancer Res"},{"key":"2026020403000818700_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: new insights into its biological function and use in tumor immunotherapy","volume":"3","author":"Egen","year":"2002","journal-title":"Nat Immunol"},{"key":"2026020403000818700_bib25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2026020403000818700_bib26","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"2026020403000818700_bib27","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"2026020403000818700_bib28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"2026020403000818700_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"2026020403000818700_bib30","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/intimm\/dxm091","article-title":"Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs","volume":"19","author":"Wong","year":"2007","journal-title":"Int Immunol"},{"key":"2026020403000818700_bib31","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026020403000818700_bib32","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","article-title":"Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors","volume":"3","author":"Thommen","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2026020403000818700_bib33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"2026020403000818700_bib34","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1038\/srep13110","article-title":"Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer","volume":"5","author":"He","year":"2015","journal-title":"Sci Rep"},{"key":"2026020403000818700_bib35","doi-asserted-by":"crossref","first-page":"656340","DOI":"10.1155\/2012\/656340","article-title":"Programmed death ligand 2 in cancer-induced immune suppression","volume":"2012","author":"Rozali","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2026020403000818700_bib36","author":"Study of BMS-936558 (nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (CheckMate 017)"},{"key":"2026020403000818700_bib37","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2026020403000818700_bib38","author":"Study of BMS-936558 (nivolumab) compared to docetaxel in previously treated metastatic non-squamous NSCLC"},{"key":"2026020403000818700_bib39","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2026020403000818700_bib40","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026020403000818700_bib41","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"2026020403000818700_bib42","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2026020403000818700_bib43","doi-asserted-by":"crossref","first-page":"LBA7_","DOI":"10.1093\/annonc\/mdw435.39","article-title":"NSCLC, metastatic CheckMate 026: a phase 3 trial of nivolumab vs investigator\u2019s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv\/recurrent programmed death ligand 1 (PD-L1)\u2212positive NSCLC","volume":"27","author":"Socinski","year":"2016","journal-title":"Ann Oncol"},{"key":"2026020403000818700_bib44","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026020403000818700_bib45","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"2026020403000818700_bib46","doi-asserted-by":"crossref","article-title":"Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)","author":"Besse","DOI":"10.1016\/S0959-8049(16)31938-4"},{"key":"2026020403000818700_bib47","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"2026020403000818700_bib48","author":"A study of atezolizumab (MPDL3280A) compared with a platinum agent (cisplatin or carboplatin) + (pemetrexed or gemcitabine) in participants with stage IV non-squamous or squamous non-small cell lung cancer (NSCLC) [IMpower110]"},{"key":"2026020403000818700_bib49","author":"A study of atezolizumab (anti-programmed death-ligand 1 PD-L1 antibody) in combination with carboplatin plus (+) nab-paclitaxel compared with carboplatin + nab-paclitaxel in participants with non-squamous non-small cell lung cancer (NSCLC) (IMpower130)"},{"key":"2026020403000818700_bib50","author":"A study of atezolizumab in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with carboplatin + nab-paclitaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) [IMpower 131]"},{"key":"2026020403000818700_bib51","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2026020403000818700_bib52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bbrc.2007.10.156","article-title":"B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma","volume":"365","author":"Matsumoto","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"2026020403000818700_bib53","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.4049\/jimmunol.172.4.2530","article-title":"B7-DC regulates asthmatic response by an IFN-\u03b3-dependent mechanism","volume":"172","author":"Matsumoto","year":"2004","journal-title":"J Immunol"},{"key":"2026020403000818700_bib54","author":"A phase 1\/2 study to evaluate MEDI4736"},{"key":"2026020403000818700_bib55","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/jco.2015.33.15_suppl.8032","article-title":"Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) [abstract]","volume":"33","author":"Rizvi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026020403000818700_bib56","first-page":"iv426","article-title":"Clinical activity and safety of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer","volume":"25","author":"Antonia","year":"2014","journal-title":"Ann Oncol"},{"key":"2026020403000818700_bib57","author":"A global study to assess the effects of MEDI4736, given as monotherapy or in combination with tremelimumab determined by PD-L1 expression versus standard of care in patients with locally advanced or metastatic non small cell lung cancer (ARCTIC)"},{"key":"2026020403000818700_bib58","author":"Phase III open label first line therapy study of MEDI 4736 (durvalumab) with or without tremelimumab versus SOC in non small-cell lung cancer (NSCLC) (MYSTIC)"},{"key":"2026020403000818700_bib59","author":"Gulley","year":"2015"},{"key":"2026020403000818700_bib60","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10637-015-0243-5","article-title":"Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer","volume":"33","author":"Horinouchi","year":"2015","journal-title":"Invest New Drugs"},{"key":"2026020403000818700_bib61","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026020403000818700_bib62","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026020403000818700_bib63","author":"Phase 3 trial in squamous non small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin"},{"key":"2026020403000818700_bib64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2026020403000818700_bib65","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer","volume":"34","author":"Reck","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026020403000818700_bib66","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1200\/jco.2009.27.15_suppl.8071","article-title":"Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract]","volume":"27","author":"Zatloukal","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026020403000818700_bib67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026020403000818700_bib68","author":"A study of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with lung cancer (MK-3475\u2013021\/KEYNOTE-021)"},{"key":"2026020403000818700_bib69","doi-asserted-by":"crossref","first-page":"9027","DOI":"10.1200\/JCO.2016.34.15_suppl.9027","article-title":"Phase I\/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H [abstract]","volume":"34","author":"Gubens","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026020403000818700_bib70","author":"Study of platinum+pemetrexed chemotherapy with or without pembrolizumab (MK-3475) in participants with first line metastatic non-squamous non-small cell lung cancer (MK-3475\u2013189\/KEYNOTE-189)"},{"key":"2026020403000818700_bib71","author":"A study of carboplatin-paclitaxel\/nab-paclitaxel chemotherapy with or without pembrolizumab (MK-3475) in adults with first line metastatic squamous non-small cell lung cancer (MK-3475\u2013407\/KEYNOTE-407)"},{"key":"2026020403000818700_bib72","article-title":"Treatment options for advanced non-small cell lung cancer: effectiveness, value and value-based price benchmarks","author":"Institute for Clinical and Economic Review","year":"2016"},{"key":"2026020403000818700_bib73","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov"},{"key":"2026020403000818700_bib74","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1038\/srep20090","article-title":"Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer","volume":"6","author":"Sheng","year":"2016","journal-title":"Sci Rep"},{"key":"2026020403000818700_bib75","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/2051-1426-3-S2-P302","article-title":"PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer","volume":"3","author":"Grabosch","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2026020403000818700_bib76","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"2026020403000818700_bib77","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"2026020403000818700_bib78","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00428-016-1910-4","article-title":"Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients","volume":"468","author":"Ilie","year":"2016","journal-title":"Virchows Arch"},{"key":"2026020403000818700_bib79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamaoncol.2015.4685","article-title":"PD-L1 testing in cancer: challenges in companion diagnostic development","volume":"2","author":"Hansen","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026020403000818700_bib80","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-2375","article-title":"Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer","author":"Ratcliffe","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026020403000818700_bib81","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","author":"Rimm","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026020403000818700_bib82","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2026020403000818700_bib83","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"2026020403000818700_bib84","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026020403000818700_bib85","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab Invest"},{"key":"2026020403000818700_bib86","article-title":"EBUS-TBNA as a promising method for the evaluation of tumor PD-L1 expression in lung cancer","author":"Sakakibara","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"2026020403000818700_bib87","doi-asserted-by":"crossref","first-page":"31745","DOI":"10.1038\/srep31745","article-title":"Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment","volume":"6","author":"Lizotte","year":"2016","journal-title":"Sci Rep"},{"key":"2026020403000818700_bib88","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2017.01.004","article-title":"Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas","volume":"75","author":"Kim","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026020403000818700_bib89","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1172\/JCI87324","article-title":"Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma","volume":"126","author":"Daud","year":"2016","journal-title":"J Clin Invest"},{"key":"2026020403000818700_bib90","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"2026020403000818700_bib91","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","article-title":"Biomarkers associated with checkpoint inhibitors","volume":"27","author":"Manson","year":"2016","journal-title":"Ann Oncol"},{"key":"2026020403000818700_bib92","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer","volume":"112","author":"Abiko","year":"2015","journal-title":"Br J Cancer"},{"key":"2026020403000818700_bib93","first-page":"tr8","article-title":"The Jak-STAT pathway stimulated by interferon \u03b3","volume":"2004","author":"Horvath","year":"2004","journal-title":"Sci STKE"},{"key":"2026020403000818700_bib94","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"2026020403000818700_bib95","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"2026020403000818700_bib96","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"2026020403000818700_bib97","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2026020403000818700_bib98","first-page":"237","article-title":"Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma","volume":"11","author":"Kim","year":"2014","journal-title":"Cancer Biol Med"},{"key":"2026020403000818700_bib99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/2326-6066.CIR-14-0126","article-title":"Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication","volume":"4","author":"Ali","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2026020403000818700_bib100","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/1078-0432.CCR-15-1070","article-title":"Blockade of programmed death 1 augments the ability of human T cells engineered to target NY-ESO-1 to control tumor growth after adoptive transfer","volume":"22","author":"Moon","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026020403000818700_bib101","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cell.2016.03.031","article-title":"combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling","volume":"165","author":"Minn","year":"2016","journal-title":"Cell"},{"key":"2026020403000818700_bib102","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026020403000818700_bib103","author":"Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC"},{"key":"2026020403000818700_bib104","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026020403000818700_bib105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/875512251302900207","article-title":"Ipilimumab-Induced pneumonitis: a case report","volume":"29","author":"Mis","year":"2013","journal-title":"J Pharm Technol"},{"key":"2026020403000818700_bib106","first-page":"22","article-title":"Ipilimumab associated autoimmune alveolitis responding to corticosteroids","volume":"4","author":"Rao","year":"2013","journal-title":"J Med Cases"},{"key":"2026020403000818700_bib107","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026020403000818700_bib108","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026020403000818700_bib109","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2026020403000818700_bib110","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"2026020403000818700_bib111","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"2026020403000818700_bib112","doi-asserted-by":"crossref","first-page":"44173","DOI":"10.1038\/srep44173","article-title":"PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"2026020403000818700_bib113","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026020403000818700_bib114","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026020403000818700_bib115","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"2026020403000818700_bib116","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/14\/8\/1248\/66715222\/annalsats_14_8_1248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/14\/8\/1248\/66715222\/annalsats_14_8_1248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:00:27Z","timestamp":1770192027000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/14\/8\/1248\/8453623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":116,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,1]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201702-152fr","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8]]},"published":{"date-parts":[[2017,8,1]]}}}